Catégorie : Essais Cliniques

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes, Santé Canada, dernière version octobre 2018

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique.   Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]

Lire la suite

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine, Samuel T. Wilkinson et al., 2019

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine Samuel T. Wilkinson, David H. Howard,  Susan H. Busch JAMA Published online August 2, 2019 doi:10.1001/jama.2019.10728   Major depressive disorder (MDD) affects approximately 17.3 million adults in the United States,1 with a 12-month and lifetime prevalence of 10.4% and 20.6%, respectively.2 Conducting clinical trials and developing new treatments for depression can be difficult because of spontaneous recovery rates and placebo effects.3 In addition, many patients with chronic and refractory MDD do not experience clinical improvement even after several treatment courses. There is growing interest in the use of exercise and improved nutrition to treat depression,4 [...]

Lire la suite

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer, Michele Moreau et al., 2019

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer Michele Moreau, Udoka Ibeh, Kaylie Decosmo Noella Bih, Sayeda Yasmin-Karim, Ngeh Toyang, Henry Lowe5 and Wilfred Ngwa Frontiers in Oncology, July 2019, Vol. 9, article 660. doi: 10.3389/fonc.2019.00660   Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new [...]

Lire la suite

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy, James W.B. Elsey, 2017

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, Vol 3, 1-11 DOI: 10.1177/2050324517723232   Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings [...]

Lire la suite

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors, Roland R. Griffiths et al., 2017

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Roland R. Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards3, Robert Jesse, Katherine A. MacLean, Frederick S. Barrett, Mary P. Cosimano and Maggie A. Klinedinst Journal of Psychopharmacology, 2017, 1–21 DOI: 10.1177/0269881117731279   Abstract Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very [...]

Lire la suite

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis, Robin L. Carhart-Harris et al., 2012

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Robin L. Carhart-Harris, Robert Leech, David Erritzoe, Tim M. Williams, James M. Stone, John Evans, David J. Sharp, Amanda Feilding, Richard G. Wise, and David J. Nutt Schizophrenia Bulletin, 2012 doi: 10.1093/schbul/sbs117   model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamo-cortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on changes in FC between the default-mode- (DMN) and task-positive network (TPN). Spontaneous activity in the DMN is orthogonal [...]

Lire la suite

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybine, Robin L. Carhart-Harris et al., 2012

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybine Robin L. Carhart-Harris, David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, Robert Leech, Andrea L. Malizia, Kevin Murphy, Peter Hobden, John Evans, Amanda Feilding, Richard G. Wise, and David J. Nutt PNAS, Proceedings of the National Academy of Sciences of the USA, 2012, 109, (6), 2138-2143. doi:10.1073/pnas.1119598109 www.pnas.org/lookup/suppl/doi:10.1073/pnas.1119598109/-/DCSupplemental.   Abstract Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about howthey work in the brain. Here we used psilocybin, a classic [...]

Lire la suite

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study, Alicia L. Danforth, Charles S. Grob et al., 2018

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9   Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]

Lire la suite

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer, Charles S. Grob et al., 2010

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob,  Alicia L. Danforth,  Gurpreet S. Chopra,  Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt,  George R. Greer Archive of  General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116   Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]

Lire la suite

The International Congress on Clinical Trials in Cannabis, 24-25 October 2019, London UK

Welcome letter  |  Program  |  Registration  |  Abstract Submission Abstracts topics Phytocannabinoid study – strains, chemovars, entourage and molecules. Pharamacokinetics and pharmacodynamics of cannabinoids Prediction of response to cannabinoid treatment Clinical trials targeting Pain, GI Disorders, Palliative Care, Psychiatry and Neurological disorders New designs for cannabis clinical trials (including pragmatic trials and n=1) Clinical Registries Observational / Epidemiological studies: findings, interpretations, plans Phase 2/3/4 study findings and designs (including special populations) Meta- and composite- analyses: findings and methodology Regulatory, licensing, and development programme issues and plans Cannabinoid trial best conduct including GCP and site training Assessing safety of cannabinoid medications Innovative [...]

Lire la suite